Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 6,734 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Scheduling Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Melodic-based Communication Therapy for Promoting Spoken Language Development in Individuals With Nonverbal Autism

NCT04679974
View directory record Official record
Conditions
Nonverbal and Low Verbal Autism
Interventions
Melodic-based Communication Therapy
Behavioral
Lead sponsor
Loma Linda University
Other
Eligibility
3 Years to 10 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Not applicable Interventional Results available

A Patient Advocate to Improve Real-world Asthma Management for Inner City Adults

NCT01972308
View directory record Official record
Conditions
Asthma, Communication
Interventions
Patient Advocate, Usual Care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 30, 2026, 6:30 PM EDT
Active, not recruiting Phase 3 Interventional

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Capivasertib, Paclitaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
22
States / cities
Whittier, California • Fort Myers, Florida • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 30, 2026, 6:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Biomarkers for Peripheral Circadian Clocks in Humans

NCT06296823
View directory record Official record
Conditions
Circadian Rhythms
Interventions
Simulated jetlag protocol
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
17 Years to 35 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

NCT00109707
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 30, 2026, 6:30 PM EDT
Terminated Phase 4 Interventional Results available

Posterior Spinal Fusion With Two Energy Dissection Techniques

NCT02465099
View directory record Official record
Conditions
Scoliosis
Interventions
Ultrasonic Dissection (UD), Electrocautery Dissection (ED)
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
10 Years to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Madera, California • Wilmington, Delaware • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma

NCT01839799
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, Abraxane, FOLFIRINOX, Chemoradiation
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 30, 2026, 6:30 PM EDT
Recruiting Not applicable Interventional

A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial

NCT05805709
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Birmingham, Alabama • New Haven, Connecticut • Weston, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combined Pharmaco/Behavior Therapy in Adolescent Smokers

NCT00330187
View directory record Official record
Conditions
Nicotine Dependence, Nicotine Use Disorder
Interventions
Bupropion SR, Contingency Management, Placebo
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Computer Assisted Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Comprehensive Stepped-Care Approach

NCT01522287
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Computer-Assisted Cognitive Behavior Therapy (BT STEPS)
Behavioral
Lead sponsor
Center for Psychological Consultation
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

NCT03502668
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
ASTX727 LD, ASTX727 SD
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

NCT03433313
View directory record Official record
Conditions
Breast Cancer
Interventions
EG12014, Herceptin
Drug
Lead sponsor
EirGenix, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Farmington Hills, Michigan • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Not applicable Interventional Results available

Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans

NCT01772550
View directory record Official record
Conditions
Contrast Enhanced Computed Tomography
Interventions
20GA BD Nexiva Diffusics, 18GA Conventional Catheter
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 30, 2026, 6:30 PM EDT
Terminated Phase 1Phase 2 Interventional

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

NCT01455389
View directory record Official record
Conditions
Lung Cancer
Interventions
DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine
Drug
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 30, 2026, 6:30 PM EDT
Terminated Phase 3 Interventional

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

NCT05964413
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
vilobelimab, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Hialeah, Florida • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

NCT05616013
View directory record Official record
Conditions
Obesity, Obese, Overweight or Obesity
Interventions
Bimagrumab, Semaglutide, Placebo
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Active, not recruiting Not applicable Interventional

Addressing Diabetes by Elevating Access to Nutrition

NCT05228860
View directory record Official record
Conditions
Diabetes, Obesity, Lifestyle, Healthy
Interventions
Vida Sana (a Group Lifestyle Intervention), Supplemental Healthy Food Deliveries
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Concord, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

NCT03148418
View directory record Official record
Conditions
Cancer
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
44
States / cities
Scottsdale, Arizona • Los Angeles, California • San Marcos, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Not applicable Interventional

Improving Adherence to Pharmacological Treatment

NCT00848224
View directory record Official record
Conditions
Medication Adherence
Interventions
systems-based and pharmacist-mediated program
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
30 Years to 85 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 4 Interventional Results available

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

NCT00619892
View directory record Official record
Conditions
Panic Disorder
Interventions
quetiapine XR, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Not applicable Interventional

Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer

NCT03435471
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer
Interventions
Prophylactic Swallowing Home Exercise Program, Clinician-Directed Prophylactic Swallowing Exercises
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 30, 2026, 6:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

NCT05420064
View directory record Official record
Conditions
BRCA1 Mutation, POLD1 Gene Mutation, CDKN2A Mutation, BRCA2 Mutation, POLE Gene Mutation, APC Gene Mutation, ATM Gene Mutation, MLH1 Gene Mutation, BARD1 Gene Mutation, MSH2 Gene Mutation, BRIP1 Gene Mutation, MSH6 Gene Mutation, CHEK2 Gene Mutation, PMS2 Gene Mutation, PALB2 Gene Mutation, EPCAM Gene Mutation, RAD51C Gene Mutation, BMPR1A Gene Mutation, RAD51D Gene Mutation, SMAD4, PTEN Gene Mutation, GREM1
Interventions
Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
25 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Psychotherapy for Bipolar II Depression, Pilot Study, Phase II

NCT00411463
View directory record Official record
Conditions
Bipolar II Disorder
Interventions
Interpersonal and Social Rhythm Therapy (IPSRT-BPII), Seroquel
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 30, 2026, 6:30 PM EDT